Epilepsy is a disease of unknown cause to the end, mainly characterized by the occurrence of unprovoked seizures. A seizure is a temporary change, in turn, reactivity or physiological change in part or whole brain. Seizures are divided into partial, generalized and unclassified. The concept of drug-resistant epilepsy may seem somewhat obvious and intuitively understandable, but not yet developed a detailed definition of commonly accepted. As a result, doctors and researchers use very different criteria and, in some cases, even give up the precise criteria, which makes it difficult to compare the results of clinical trials and the development of practical guidelines. In the treatment of epilepsy, there is no one standard way to proceed. The aim of epilepsy treatment is complete seizure control and getting the least side effects during treatment with antiepileptic drugs. The drug should be tailored to the type of seizure or epilepsy syndrome, the frequency and severity of seizures. The choice depends on the type of drug seizures, for example, primary generalized seizures, valproic acid is used, and secondarily generalized seizures and partial carbamazepine. Older-generation drugs (phenytoin, phenobarbital, primidone) is slowly becoming obsolete. However, may be prescribed for specific indications. There is also a large group of new drugs (lamotrigine, vigabatrin, oxcarbazepine, gabapentin, levetiracetam, felbamat, topiramate, tiagabine), which are becoming increasingly popular. The emergence of a new generation of drugs gave them some advantage over older-generation drugs. They are characterized by greater specificity of action, improved pharmacokinetic properties, better evaluation of clinical trials and less side effects. These drugs are in clinical trials, and direct observation of lessons can be drawn that they are very useful in some types of epilepsy. There is no doubt that further research and observation. This article presents a brief overview of the pharmacokinetic properties of selected drugs as well as potential interactions between them. Properly processes of absorption, metabolism, distribution and elimination of drugs determine the appropriate therapeutic efficacy. The success of treatment can also significantly affect the pharmacokinetic and pharmacodynamic interactions.

metabolism of drugs, the reaction of the first phase oxidation of drugs, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4, reaction of the second phase, glucuronidation, valproic acid, UDP-glucuronosyltransferases, elimination